Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | PTPRA | P18433 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | CDK9 | P50750 | 1/20 | 0.41 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.41 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.41 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.41 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.41 |
| ▸ | CASP3 | P42574 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL555036 | 1.00 | MAPT (0.50) | MAPTSMN1; SMN2HTTDNM1LMNA | |
| SCHEMBL412018 | 1.00 | MAPT (0.50) | MAPTSMN1; SMN2HTTDNM1LMNA | |
| Hydrochloric Acid SCHEMBL1140275 | 0.98 | MAPT (0.49) | MAPTSMN1; SMN2HTTDNM1LMNA | |
| Hydrochloric Acid SCHEMBL6422363 | 0.98 | MAPT (0.49) | MAPTSMN1; SMN2HTTDNM1LMNA | |
| Phosphoric Acid SCHEMBL8362755 | 0.85 | MAPT (0.43) | MAPTSMN1; SMN2HTTDNM1LMNA | |
| SCHEMBL5514976 | 0.83 | MAPT (0.48) | MAPTSMN1; SMN2HTTDNM1LMNA | |
| SCHEMBL12227832 | 0.82 | FDPS (0.54) | SMN1; SMN2HTTLMNAKDM4EPTPRA | |
| SCHEMBL14157786 | 0.82 | MAPT (0.44) | MAPTHTTLMNAKDM4EMEN1 | |
| Hydrochloric Acid SCHEMBL4829746 | 0.81 | MAPT (0.42) | MAPTHTTLMNAKDM4EMEN1 | |
| SCHEMBL6086624 | 0.81 | MAPT (0.57) | MAPTSMN1; SMN2HTTDNM1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1244 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4714452-A1 | METHODS FOR TREATING SARS COV-2 INFECTIONS | Gilead Sciences, Inc. (US) | 2026-03-25 | — | — | EP | claimed |
| CN-118766947-A | Methods for treating SARS CoV-2 infection | 吉利德科学公司 | 2024-10-15 | — | — | CN | claimed |
| CN-118662520-A | Methods for treating SARS CoV-2 infection | 吉利德科学公司 | 2024-09-20 | — | — | CN | claimed |
| US-11660307-B2 | Methods for treating SARS CoV-2 infections | GILEAD SCIENCES, INC. (US) | 2023-05-30 | — | — | US | claimed |
| CN-105037243-B | A kind of paclitaxel lateral chain phenylisoserine derivative and preparation method and application | 贵州大学 | 2017-09-05 | — | — | CN | claimed |
| CN-106632297-A | Docetaxel side chain 2'-derived novel taxanes antitumor compound as well as synthesis method and application thereof | 吉林医药学院 | 2017-05-10 | — | — | CN | claimed |
| CN-105030659-A | Gel for body surface wound and preparation method of gel | UNIV GUIZHOU | 2015-11-11 | — | — | CN | claimed |
| CN-105037243-A | Paclitaxel side-chain phenyl serine derivative, and preparation method and application thereof | UNIV GUIZHOU | 2015-11-11 | — | — | CN | claimed |
| US-20140371474-A1 | CABAZITAXEL, RELATED COMPOUNDS AND METHODS OF SYNTHESIS | Shanghai Bioman Phama Limited (CN) | 2014-12-18 | — | — | US | claimed |
| EP-2768819-A1 | CABAZITAXEL, RELATED COMPOUNDS AND METHODS OF SYNTHESIS | Shanghai Bioman Pharma Limited (CN) | 2014-08-27 | — | — | EP | claimed |
| US-5290957-A | Process for the stereoselective preparation of phenylisoserine derivatives used in making taxols | RHONE POULENC RORER S.A. (FR) | 1994-03-01 | — | — | US | claimed |
| EP-0558623-A1 | METHOD FOR PREPARING TAXANE DERIVATIVES, NOVEL DERIVATIVES THEREBY OBTAINED AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME. | RHONE POULENC RORER SA (FR) | 1993-09-08 | — | — | EP | claimed |
| WO-1993010076-A1 | SYNTHESIS AND OPTICAL RESOLUTION OF THE TAXOL SIDE CHAIN AND RELATED COMPOUNDS | THE UNIVERSITY OF MISSISSIPPI (US) | 1993-05-27 | — | — | WO | claimed |
| EP-0414610-B1 | PROCESS FOR THE ENANTIOSELECTIVE PREPARATION OF PHENYLISOSERINE DERIVATIVES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 1993-05-26 | — | — | EP | claimed |
| EP-0530285-A1 | PROCESS FOR THE ENANTIOSELECTIVE PREPARATION OF PHENYLISOSERIN DERIVATIVES. | RHONE POULENC RORER SA (FR) | 1993-03-10 | — | — | EP | claimed |
| EP-0530286-A1 | PROCESS FOR THE STEREOSELECTIVE PREPARATION OF PHENYLISOSERIN DERIVATIVES. | RHONE POULENC RORER SA (FR) | 1993-03-10 | — | — | EP | claimed |
| WO-1992009589-A1 | METHOD FOR PREPARING TAXANE DERIVATIVES, NOVEL DERIVATIVES THEREBY OBTAINED AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | RHONE-POULENC RORER S.A. (FR) | 1992-06-11 | — | — | WO | claimed |
| WO-1991017976-A1 | PROCESS FOR THE ENANTIOSELECTIVE PREPARATION OF PHENYLISOSERIN DERIVATIVES | RHONE-POULENC RORER S.A. (FR) | 1991-11-28 | — | — | WO | claimed |
| WO-1991017977-A1 | PROCESS FOR THE STEREOSELECTIVE PREPARATION OF PHENYLISOSERIN DERIVATIVES | RHONE-POULENC RORER S.A. (FR) | 1991-11-28 | — | — | WO | claimed |
| EP-0414610-A1 | Process for the enantioselective preparation of phenylisoserine derivatives | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 1991-02-27 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11660307-B2 | Methods for treating SARS CoV-2 infections | ACE2, ACE, PNP | MAPT 2507/4885SMN1; SMN2 1178/4885HTT 2900/4885 |
| US-20140371474-A1 | CABAZITAXEL, RELATED COMPOUNDS AND METHODS OF SYNTHESIS | PSAT1, PLK1, MYC | MAPT 678/4885SMN1; SMN2 4494/4885HTT 3400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.